Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
1.600
-0.060 (-3.61%)
At close: Mar 28, 2025, 4:00 PM
1.611
+0.011 (0.69%)
After-hours: Mar 28, 2025, 7:55 PM EDT

Company Description

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally.

It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFβ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies.

In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884.

The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme.

The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.

Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus Inc.
Agenus logo
Country United States
Founded 1994
IPO Date Feb 4, 2000
Industry Biotechnology
Sector Healthcare
Employees 316
CEO Garo Armen

Contact Details

Address:
3 Forbes Road
Lexington, Massachusetts 02421-7305
United States
Phone 781 674 4400
Website agenusbio.com

Stock Details

Ticker Symbol AGEN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001098972
CUSIP Number 00847G804
ISIN Number US00847G8042
Employer ID 06-1562417
SIC Code 2836

Key Executives

Name Position
Dr. Garo H. Armen Ph.D. Founder, Executive Chairman and Chief Executive Officer
Christine M. Klaskin Vice President of Finance, Principal Financial Officer and Principal Accounting Officer
Dr. Steven J. O'Day M.D., Ph.D. Chief Medical Officer
Craig Winter Chief Information Officer
Zack Armen Head of Investor Relations and Corporate Development
Stefanie Perna-Nacar Chief Communications and Government Relations Officer
Tracy Mazza Clemente Chief People Officer
Alfred Dadson Chief Manufacturing Officer
Eric Humes Chief Quality Officer
Dr. Todd Jude Yancey M.D. Member of Advisory Board and Chief Strategic Advisor

Latest SEC Filings

Date Type Title
Mar 17, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Feb 26, 2025 8-K Current Report
Feb 10, 2025 8-K Current Report
Dec 5, 2024 8-K Current Report
Nov 27, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report